Development and characterization of standard reagents for cell-based prepandemic influenza vaccine products
Open Access
- 2 March 2020
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 16 (9) , 2245-2251
Abstract
Outbreaks of infection by novel avian influenza virus strains in humans cause public health issues worldwide, and the development of vaccines against such novel strains is the most effective method for the prevention of these virus outbreaks. All types of vaccines must be tested for potency before use; thus, quantitative potency assays are needed for influenza vaccines. The single radial immunodiffusion (SRID) assay is considered the gold standard for quantification of influenza virus antigens, and the SRID reference reagents are essential for the determination of vaccine potency. However, it remains debatable whether reference reagents derived from egg-based vaccine platforms can be used to precisely quantify non-egg-derived vaccines; thus, influenza vaccine production using cell-based platforms has attracted increasing attention. To evaluate the utility of reference reagents derived from a cell-based influenza vaccine platform, we prepared cell-based reference reagents from MDCK cell-grown viruses and compared them with egg-derived reference reagents. A primary liquid standard (PLS) was purified from cell-derived candidate influenza vaccine viruses, and hemagglutinin (HA) antigen content was determined by a densitometric method. The produced PLS could be stored at 4°C for more than 10 months. We also established a simple HA protein purification method for goat antiserum preparation, and the performance of the resulting antiserum was compared to that of standard reagents obtained using different production platforms. The results of this study indicate that these reference reagents can be used for both cell-based and egg-based production platforms and that the differences between these two types of platforms are negligible.Keywords
Funding Information
- Ministry of Science and Technology, Taiwan (R.O.C. 102-2622-B-400-001-CC2; 103-2622-B-400-001-CC2)
This publication has 31 references indexed in Scilit:
- Reviewing the History of Pandemic Influenza: Understanding Patterns of Emergence and TransmissionPathogens, 2016
- Serological Evidence of Influenza A Viruses in Frugivorous Bats from AfricaPLOS ONE, 2015
- Flucelvax (Optaflu) for seasonal influenzaExpert Review of Vaccines, 2015
- Collaborative studies on the development of national reference standards for potency determination of H7N9 influenza vaccineHuman Vaccines & Immunotherapeutics, 2015
- Current and Emerging Cell Culture Manufacturing Technologies for Influenza VaccinesBioMed Research International, 2015
- A cell-based backup to speed up pandemic influenza vaccine productionTrends in Microbiology, 2012
- Clinical Efficacy of Cell Culture–Derived and Egg‐Derived Inactivated Subunit Influenza Vaccines in Healthy AdultsClinical Infectious Diseases, 2010
- Influenza vaccine: The challenge of antigenic driftVaccine, 2007
- Quantification of haemagglutinin of influenza Tween-ether split vaccines by immunodiffusionVaccine, 1985
- An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: Application for potency determinations of inactivated whole virus and subunit vaccinesJournal of Biological Standardization, 1977